Treatment-Related Adverse Events of Antibody Drug Conjugates Identified
MONDAY, Nov. 21, 2022 (HealthDay News) -- Adverse effects associated with antibody-drug conjugates (ADCs) have been described in a review and meta-analysis published online Nov. 21 in Cancer.
Youwen Zhu, from Central South University in Changsha, China, and colleagues conducted a systematic review and meta-analysis of data obtained between Jan. 1, 2000, and June 7, 2022, to examine mechanisms of toxicity for ADCs. The primary outcome was the incidence of all-grade and grade ≥3 treatment-related adverse events. A total of 2,511 records were identified that included 169 clinical trials and 22,492 patients.
The researchers found that the overall incidence of treatment-related adverse events was 91.2 and 46.1 percent for all-grade adverse events and grade ≥3 adverse events, respectively. Lymphopenia, nausea, neutropenia, blurred vision, and peripheral neuropathy were the most common all-grade adverse events (53.0, 44.1, 43.7, 40.5, and 39.6 percent, respectively), while the most common grade ≥3 adverse events were neutropenia, hypoesthesia, thrombocytopenia, febrile neutropenia, and lymphopenia (31.2, 23.3, 22.6, 21.2, and 21.0 percent, respectively).
"Different ADCs appear to vary in their treatment-related adverse events," one coauthor said in a statement. "Our results provide an important reference for clinicians and patients on how to address ADCs' toxicity in clinical practice."
Related Posts
Deer Are Spreading Lyme Ticks in Suburban Backyards
TUESDAY, Sept. 20, 2022 (HealthDay News) -- They look so cute, grazing quietly...
Less Than One in Three Patients Participates in Cardiac Rehab Following TAVR
MONDAY, Oct. 16, 2023 (HealthDay News) -- Less than one-third of patients who...
For Young Workers, Insomnia Cuts Productivity
MONDAY, July 17, 2023 (HealthDay News) -- A new study from Australia tied some...
Un historial de cáncer no aumenta la vulnerabilidad a una COVID grave
JUEVES, 6 de mayo de 2022 (HealthDay News) -- Si usted tiene un historial de...